Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-14
2006-02-14
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S085000, C514S269000, C514S234500, C514S300000, C536S023500, C536S023100, C435S069100, C435S325000, C530S350000, C424S045000, C424S450000
Reexamination Certificate
active
06998391
ABSTRACT:
Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Ab1 family.
REFERENCES:
patent: 2001/0044451 (2001-11-01), Fraley et al.
patent: 2001/0047007 (2001-11-01), Fraley et al.
patent: WO 02/069903 (2002-09-01), None
U.S. Appl. No. 10/071,849, filed on Feb. 7, 2002.
Kantarjian et al. “Treatment of accelerated phase of Philadelphia chromosome positive chronic leukemia with imatinib mesylate”. Conference abstract Blood, vol. 98, No. 11, Part 1, p. 141a, 2001.
Von Hoff et al. “%-azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.” Annals of Internal Medicine, 85(2), pp. 237-245, 1976.
Sheikhnejad, G. et al., “Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine”,J. Mol. Biol., 1999, pp. 2021-2034, vol. 285.
Goffin, J. et al., “DNA methyltransferase inhibitors—state of the art”,Annals of Oncology, 2002, pp. 1699-1716, vol. 13.
Wijermans, P. et al., “Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients”,Journal of Clinical Oncology, Mar. 2000, pp. 956-962, vol. 18, No. 5.
Lyons John
Rubinfeld Joseph
SuperGen.Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Method for treating diseases associated with abnormal kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating diseases associated with abnormal kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating diseases associated with abnormal kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3662053